Fifth Third Bancorp Supernus Pharmaceuticals, Inc. Transaction History
Fifth Third Bancorp
- $27.1 Billion
- Q4 2024
A detailed history of Fifth Third Bancorp transactions in Supernus Pharmaceuticals, Inc. stock. As of the latest transaction made, Fifth Third Bancorp holds 246 shares of SUPN stock, worth $9,712. This represents 0.0% of its overall portfolio holdings.
Number of Shares
246
Previous 272
9.56%
Holding current value
$9,712
Previous $8,000
-0.0%
% of portfolio
0.0%
Previous 0.0%
Shares
22 transactions
Others Institutions Holding SUPN
# of Institutions
289Shares Held
60.8MCall Options Held
27.7KPut Options Held
11.3K-
Black Rock Inc. New York, NY10.4MShares$410 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.13MShares$242 Million0.0% of portfolio
-
Armistice Capital, LLC New York, NY5.1MShares$201 Million2.64% of portfolio
-
Dimensional Fund Advisors LP Austin, TX2.88MShares$114 Million0.02% of portfolio
-
Macquarie Group LTD Australia, C32.63MShares$104 Million0.09% of portfolio
About SUPERNUS PHARMACEUTICALS, INC.
- Ticker SUPN
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 53,495,300
- Market Cap $2.11B
- Description
- Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...